The report outlines the results of a double-blind study into the clinical outcomes following a 48-hour administration of a magnetophoresis enhanced transdermal Ibuprofen (5%) patch.
The study sought to demonstrate that OBJ’s array-back hydrogel technology could be used with third-party therapeutic drugs such as ibuprofen.
Applications for ageing population
Ibuprofen and many other similar anti-inflammatory drugs cannot be taken in tablet form for extended periods due to their impact on other organs.
OBJ’s slow-release technology could potentially be an ideal resolution to the problem, and the fact that its target markets could include the ageing population is a positive.
Broad-based results demonstrate pain reduction
There were significant differences between the active patch session and the placebo patch session for all primary outcome measures.
This indicated that participants experienced less pain and improved function during the 48-hour active patch session.
There were also significant improvements across most of the secondary outcome measures with few skin reactions to either placebo or active patches.
Slight skin redness was reported by five participants with the active patches and six participants with the placebo patches, and all associated this with the adhesive tape rather than the gel.
Impressive active knee guard device results
The results were particularly encouraging in relation to OBJ’s active knee guard device containing ibuprofen (5%).
Combined with magnetophoresis, this produced a significantly greater reduction in pain and improvement in function than the placebo device.
There was a significant improvement in participants suffering from movement-related pain.
Twenty-two participants (92%) considered themselves either better or much better following the active patch treatment.